Suppr超能文献

相似文献

1
Severe acute respiratory syndrome-coronavirus-2: Current advances in therapeutic targets and drug development.
Rev Med Virol. 2021 May;31(3):e2174. doi: 10.1002/rmv.2174. Epub 2020 Sep 23.
2
Review of studies of severe acute respiratory syndrome related coronavirus-2 pathogenesis in human organoid models.
Rev Med Virol. 2021 Nov;31(6):e2227. doi: 10.1002/rmv.2227. Epub 2021 Mar 25.
3
Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Microbiol Spectr. 2021 Oct 31;9(2):e0135221. doi: 10.1128/Spectrum.01352-21. Epub 2021 Oct 13.
4
Virus-, host-, immune-based targets for COVID-19 therapy.
Drug Discov Today. 2020 Dec;25(12):2071-2073. doi: 10.1016/j.drudis.2020.10.001. Epub 2020 Oct 6.
5
ACE2-Targeting antibody suppresses SARS-CoV-2 Omicron and Delta variants.
Signal Transduct Target Ther. 2022 Feb 9;7(1):43. doi: 10.1038/s41392-022-00913-3.
6
The role of microRNAs in modulating SARS-CoV-2 infection in human cells: a systematic review.
Infect Genet Evol. 2021 Jul;91:104832. doi: 10.1016/j.meegid.2021.104832. Epub 2021 Apr 1.
9
Ligand-centered assessment of SARS-CoV-2 drug target models in the Protein Data Bank.
FEBS J. 2020 Sep;287(17):3703-3718. doi: 10.1111/febs.15366. Epub 2020 Jun 24.

引用本文的文献

1
Recent and advanced nano-technological strategies for COVID-19 vaccine development.
Methods Microbiol. 2022;50:151-188. doi: 10.1016/bs.mim.2022.03.001. Epub 2022 Apr 18.
2
Plant-derived immuno-adjuvants in vaccines formulation: a promising avenue for improving vaccines efficacy against SARS-CoV-2 virus.
Pharmacol Rep. 2022 Dec;74(6):1238-1254. doi: 10.1007/s43440-022-00418-4. Epub 2022 Sep 20.
5
Analysis of the Spread of COVID-19 in the USA with a Spatio-Temporal Multivariate Time Series Model.
Int J Environ Res Public Health. 2021 Jan 18;18(2):774. doi: 10.3390/ijerph18020774.

本文引用的文献

1
Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2.
Commun Biol. 2021 Apr 12;4(1):475. doi: 10.1038/s42003-021-02030-3.
2
First clinical study using HCV protease inhibitor danoprevir to treat COVID-19 patients.
Medicine (Baltimore). 2020 Nov 25;99(48):e23357. doi: 10.1097/MD.0000000000023357.
3
Computational evaluation of major components from plant essential oils as potent inhibitors of SARS-CoV-2 spike protein.
J Mol Struct. 2020 Dec 5;1221:128823. doi: 10.1016/j.molstruc.2020.128823. Epub 2020 Jul 4.
4
Plant-derived natural polyphenols as potential antiviral drugs against SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibition: an analysis.
J Biomol Struct Dyn. 2021 Oct;39(16):6249-6264. doi: 10.1080/07391102.2020.1796810. Epub 2020 Jul 28.
5
The dual impact of ACE2 in COVID-19 and ironical actions in geriatrics and pediatrics with possible therapeutic solutions.
Life Sci. 2020 Sep 15;257:118075. doi: 10.1016/j.lfs.2020.118075. Epub 2020 Jul 10.
6
Covid-19: Time for a paradigm change.
Rev Med Virol. 2020 Sep;30(5):e2134. doi: 10.1002/rmv.2134. Epub 2020 Jul 3.
7
The COVID-19 Cytokine Storm; What We Know So Far.
Front Immunol. 2020 Jun 16;11:1446. doi: 10.3389/fimmu.2020.01446. eCollection 2020.
8
ACE2, Much More Than Just a Receptor for SARS-COV-2.
Front Cell Infect Microbiol. 2020 Jun 5;10:317. doi: 10.3389/fcimb.2020.00317. eCollection 2020.
9
Dexamethasone for COVID-19? Not so fast.
J Biol Regul Homeost Agents. 2020;34(3):1241-1243. doi: 10.23812/20-EDITORIAL_1-5.
10
The Nucleocapsid Protein of SARS-CoV-2: a Target for Vaccine Development.
J Virol. 2020 Jun 16;94(13). doi: 10.1128/JVI.00647-20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验